Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan-Feb;38(1):58-74.
doi: 10.1016/j.bjhh.2016.01.001. Epub 2016 Feb 5.

Guidelines on the treatment of acute myeloid leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: Project guidelines: Associação Médica Brasileira - 2015

Rosane Bittencourt  1 , Teresa Cristina Bortolheiro  2 , Maria de Lourdes Lopes Ferrari Chauffaille  3 , Evandro Maranhão Fagundes  4 , Katia Borgia Barbosa Pagnano  5 , Eduardo Magalhães Rego  6 , Wanderley Marques Bernardo  7
Affiliations

Guidelines on the treatment of acute myeloid leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: Project guidelines: Associação Médica Brasileira - 2015

Rosane Bittencourt et al. Rev Bras Hematol Hemoter. 2016 Jan-Feb.
No abstract available

PubMed Disclaimer

References

    1. University of Oxford; Oxford: 2011. Centre for Evidence Based Medicine. Available from: http://www.cebm.net [cited 21.11.12] [Internet]
    1. Berman E., Wiernik P., Vogler R., Velez-Garcia E., Bartolucci A., Whaley F.S. Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia. Cancer. 1997;80(11 Suppl):2181–2185. - PubMed
    1. Creutzig U., Ritter J., Zimmermann M., Hermann J., Gadner H., Sawatzki D.B. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. Leukemia. 2001;15(3):348–354. - PubMed
    1. Gardin C., Turlure P., Fagot T., Thomas X., Terre C., Contentin N. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood. 2007;109(12):5129–5135. - PubMed
    1. Mandelli F., Vignetti M., Suciu S., Stasi R., Petti M.C., Meloni G. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol. 2009;27(32):5397–5403. - PMC - PubMed

LinkOut - more resources